Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GILD

GILD - Gilead Sciences Inc Stock Price, Fair Value and News

$144.98-0.23 (-0.16%)
Delayed

52/100

GILD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

GILD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GILD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GILD Price Action

Last 7 days

0.7%

Last 30 days

-6.9%

Last 90 days

20.4%

Trailing 12 Months

27.9%

GILD RSI Chart

GILD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GILD Valuation

Market Cap

180.0B

Price/Earnings (Trailing)

21.15

Price/Sales (Trailing)

6.11

EV/EBITDA

17.37

Price/Free Cashflow

19.03

GILD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GILD Fundamentals

GILD Revenue

Revenue (TTM)

29.4B

Rev. Growth (Yr)

4.7%

Rev. Growth (Qtr)

2.01%

GILD Earnings

Earnings (TTM)

8.5B

Earnings Growth (Yr)

22.43%

Earnings Growth (Qtr)

-28.47%

GILD Profitability

EBT Margin

33.27%

Return on Equity

37.48%

Return on Assets

14.42%

Free Cashflow Yield

5.25%

GILD Investor Care

Dividend Yield

2.18%

Dividend/Share (TTM)

3.16

Buy Backs (1Y)

0.37%

Diluted EPS (TTM)

6.78

GILD Alerts

  • 3 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202528.7B28.9B29.1B29.4B
202427.4B27.8B28.3B28.8B
202327.0B27.4B27.4B27.1B
202227.5B27.5B27.1B27.3B
202125.6B26.6B27.5B27.3B
202022.7B22.2B23.1B24.7B
201922.3B22.4B22.4B22.4B
201824.7B23.2B22.3B22.1B
201729.1B28.5B27.5B26.1B
201632.8B32.4B31.6B30.4B
201527.5B29.2B31.4B32.6B
201413.7B17.4B20.7B24.9B
201310.0B10.3B10.7B11.2B
20128.7B9.0B9.3B9.7B
20117.8B8.0B8.2B8.4B
Get all data in R, Python etc through our Historical Stock Data APIs

About Gilead Sciences Inc

GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
 CEO
 WEBSITEgilead.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES17000

Gilead Sciences Inc Frequently Asked Questions

GILD is the stock ticker symbol of Gilead Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Gilead Sciences Inc is 179.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, GILD's PE ratio (Price to Earnings) is 21.15 and Price to Sales (PS) ratio is 6.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GILD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Gilead Sciences Inc has provided 0.05 (multiply by 100 for percentage) rate of return.